Attached files

file filename
EX-31.3 - EX-31.3 - Allergan plcd907556dex313.htm
10-K/A - 10-K/A - Allergan plcd907556d10ka.htm

Exhibit 31.4

Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934

I, Matthew M. Walsh, Chief Financial Officer, certify that:

1. I have reviewed this Amendment to the annual report on Form 10-K of Allergan plc; and

2. Based on my knowledge, this Amendment does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 29, 2020

 

By:

 

/s/ MATTHEW M. WALSH

  Matthew M. Walsh
 

Executive Vice President and Chief

Financial Officer

  (Principal Financial Officer)

 


Certification of Chief Financial Officer

Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934

I, Matthew M. Walsh, Chief Financial Officer, certify that:

1. I have reviewed this Amendment to the annual report on Form 10-K of Warner Chilcott Limited; and

2. Based on my knowledge, this Amendment does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 29, 2020

 

By:

 

/s/ MATTHEW M. WALSH

  Matthew M. Walsh
 

Executive Vice President and Chief

Financial Officer

  (Principal Financial Officer)